PSY35 A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS EVALUATING RECENTLY APPROVED BIOLOGICAL THERAPIES FOR ADULT PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN THE US, CANADA AND UK.

To compare recently approved biologics for the treatment of moderate-to-severe psoriasis by national HTA bodies in the US, Canada and UK. As more biologics are being approved, understanding the requirements of HTA, and undertaking holistic evidence generation, will play a crucial role in enabling access to the novel biologics. [Extracted from the article]